As a result of recent trials, the effectiveness of a vaccine developed in the UK has become known
The vaccine against COVID-19, developed by the University of Oxford and AstraZeneca, is very effective in preventing the virus and is also safe, according to the latest tests published in the medical journal The Lancet, Newsweek reports.
Phase three human trials also show that the vaccine is 90 percent effective against coronavirus if administered in half dose, or 62 percent if administered in two full doses. According to Lancet, so far no hospitalizations or serious illnesses have been reported in volunteers who received Oxford vaccine.
Publication of the latest test data in a peer-reviewed journal such as Lancet means that Oxford methods can now be fully understood by experts and the public.
The vaccine data have been submitted to the UK Medicines and Medical Products Regulatory Agency (MHRA) for approval. MHRA recently approved the Pfizer vaccine, the first use of which has already been conducted in the country.
Professor Andrew Pollard, Director of the Oxford Vaccine Group and Principal Investigator for Oxford Vaccine Testing, said: “Today we published an interim analysis of Phase 3 trials and showed that this new vaccine has good safety and efficacy against coronavirus. We are very grateful to our volunteers for working with us over the past eight months to bring us closer to this milestone.
In the article, the researchers said more information is needed on how effective the vaccine is for older people – those at greatest risk of severe Covid-19.